Galectin-1 links tumor hypoxia and radiotherapy.

Abstract

Radiation therapy is a main stay in treating solid tumors and plays a significant role in definitive and adjuvant therapy. Unfortunately, local control remains a challenge, in which the success of radiotherapy is largely dictated by tumor hypoxia, DNA damage repair and the antitumor immune response. Extensive efforts have therefore been devoted to targeting the factors that attenuate tumor radiosensitivity, although with limited success. Mounting evidence suggests that tumor and endothelial cells may utilize galectin-1 (Gal-1) for protection against radiation through several mechanisms. Targeting Gal-1 in combination with radiotherapy provides an exciting approach to address several radiation-prohibitive mechanisms.

• Authors: Peiwen Kuo, Quynh-Thu Le
• Journal: Glycobiology (Glycobiology) Vol. 24 Issue 10 Pg. 921-5 (Oct 2014) ISSN: 1460-2423 [Electronic] England
• PMID: 24973253 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: © The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Galectin 1
• LGALS1 protein, human

Topics

• Carcinogenesis (genetics)
• Endothelial Cells (metabolism, pathology, radiation effects)
• Galectin 1 (chemistry, metabolism)
• Humans
• Hypoxia (metabolism, pathology)
• Neoplasm Metastasis
• Neoplasms (genetics, pathology, radiotherapy)
• Neovascularization, Pathologic (genetics, pathology, radiotherapy)
• Radiation Tolerance (genetics)